source
- BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGFThe pharma company formerly known as BeiGene has plucked an experimental cancer drug from a Chinese biotech, aiming to go broader than its competitors. BeOne Medicines said it signed a license and…Endpoints · 3mo ago↗ source
- Incyte claims double Phase 3 win in vitiligo, will file for approvalIncyte intends to seek approval of its JAK1 inhibitor pill in the skin disease nonsegmental vitiligo after the drug, povorcitinib, hit in twin Phase 3 trials. The company revealed the successes ...Endpoints · 3mo ago↗ source
- STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data neededEli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news today